Outcomes from this study should provide complementary support to TOP2A knockdown results for demonstrating the critical role of Topo II inhibition in mediating the therapeutic efficacy of osimertinib in EGFRm NSCLC cells. The gene discussed is TOP2A; the disease is non-small cell lung carcinoma.